



DOCKET NO: L0461.70078US00


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Old et al.  
Serial No: 09/462,929  
Confirmation No: 5664  
Filed: July 15, 1998  
For: CANCER ASSOCIATED ANTIGENS AND USES  
THEREFOR  
Examiner: Sisson, Bradley L.  
Art Unit: 1634

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to **Mail Stop AMENDMENT**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 1450, on the 2nd day of October, 2006.

  
Sylvana Householder

---

**Mail Stop AMENDMENT**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT PURSUANT TO 37 CFR 1.821**

Sir:


Submitted herewith for filing in connection with the above-referenced patent application is a labeled, computer readable copy of the Sequence Listing included in the application.

I hereby state that the content of the compact disc copies (COPY 1 and COPY 2) and the computer readable copy for the above-referenced patent application are the same as required by 37 CFR 1.821(f).


Early favorable consideration of the patent application is respectfully solicited.

Dated: October 2, 2006

Respectfully submitted,

By:   
John R. Van Amsterdam, Reg. No. 40,212  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2211  
Telephone: (617) 646-8233

x10/01/06x



## Notice to Comply

Application No.	Applicant(s)	
09/462,929	OLD ET AL.	
Examiner	Art Unit	
Bradley L. Sisson	1634	

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: The amendment of 19 July 2006 makes reference to SEQ ID NOs. 819-822, yet the sequence listing only provides reference to SEQ ID NOs. 1 to 816. The two must match in number and composition.

#### Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

Continuation of 1(c) Other: The amendment to the specification received 19 July 2006 inserted SEQ ID NOs. to representations of nucleotides found on page 78 of the disclosure. A review of the disclosure finds but one Sequence Listing having been filed, and that was on 14 January 2000, and contained representations of 816 sequences. The amendment of 19 July 2006 introduces SEQ ID NO. 819-822, yet, for reasons indicated above, there does not appear to be such an entry in the Sequence Listing. In the absence of evidence to the contrary, applicant needs to comply with the attached Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures."



BRADLEY L. SISSON  
PRIMARY EXAMINER

GROUP 1800 1630